Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

CLIMB BIO, INC. (CLYM) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

CLIMB BIO, INC. (CLYM), most recent 12 months reported: net loss $57.62M, free cash flow -$54.54M. Latest balance sheet on file: liquid cash $183.12M. From SEC filings. Others in Pharmaceutical Preparations: PERSPECTIVE THERAPEUTICS, INC. · CDT EQUITY INC. · Cingulate Inc. · Cellectar Biosciences, Inc. · SNOWDRIFT PARENT CORPORATION · COMPASS PATHWAYS PLC · CNBX PHARMACEUTICALS INC. · CNS Pharmaceuticals, Inc.

Stock screener

Watchlist